Galmed Pharmaceuticals (GLMD)
(Delayed Data from NSDQ)
$3.10 USD
-0.27 (-8.01%)
Updated Nov 6, 2024 04:00 PM ET
Pre-Market: $3.25 +0.15 (4.84%) 9:10 AM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.10 USD
-0.27 (-8.01%)
Updated Nov 6, 2024 04:00 PM ET
Pre-Market: $3.25 +0.15 (4.84%) 9:10 AM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Intercept (ICPT) Gains on Earnings and Revenue Beat in Q3
by Zacks Equity Research
Intercept's (ICPT) revenues beat estimates, owing to strong Ocaliva sales in the third quarter of 2018.
Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers
by Zacks Equity Research
Intercept (ICPT) gains on a better-than-expected second quarter as loss narrows and sales surpass estimates on a significant recovery in Ocaliva.
Galmed Pharmaceuticals (GLMD) Reports Q2 Loss
by Zacks Equity Research
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of -6.25% and 0.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical-Drugs Stock Outlook: No Respite from Near-Term Pain
by Zacks Equity Research
Small drugmakers, in general, are having a rather poor year, the principle reason being failure of key pipeline candidates in pivotal studies.
What's in Store for Universal Health's (UHS) Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q2 is likely to benefit from strong performances at its Acute Care and Behavioral Health segments.
What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q2 results are likely to be aided by a strong top line, riding on higher admissions, partially offset by increasing costs.
Galmed (GLMD) Soars on Positive NASH Data on Aramchol
by Zacks Equity Research
Shares of Galmed Pharmaceuticals (GLMD) surges significantly following positive top-line results on lead candidate Aramchol in NASH patients.
3 Reasons Why Galmed Pharmaceuticals (GLMD) is a Great Momentum Stock
by Zacks Equity Research
Momentum stock investors will love Galmed Pharmaceuticals (GLMD) as it has favorable price performance and is also seeing positive estimate revisions.
Galmed Pharmaceuticals (GLMD) Catches Eye: Stock Gains 15.7%
by Zacks Equity Research
Galmed Pharmaceuticals Ltd. (GLMD) shares jumped nearly 16% in the last trading session.